Protocol No.: GO45322

A PHASE II PROSPECTIVE, OPEN-LABEL SAFETY STUDY OF INAVOLISIB AND FULVESTRANT WITH OR WITHOUT PALBOCICLIB IN PARTICIPANTS WITH PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER AND TYPE 2 DIABETES
Principal Investigator
Jiang, Bei
Phase
II
Age Group
Adult
Applicable Disease Site
Breast Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Emily Hawkins, BSN
Research Nurse
Phone: +1 304-293-7375

View on ClinicalTrials.gov